Qatar is regulated by the Ministry of Public Health (MOPH), and within it the Pharmacy and Drug Control Department (PDCD). Product registration and pricing sit together in the same section, which tells you something useful about how the process works: price is not an afterthought, it is part of the file.
Raised Pharma supports manufacturers and brand owners preparing for the Qatari market: classification, dossier preparation, GMP evidence, stability data and labelling review.
This is the single most important thing to understand about Qatar, and it catches out nutraceutical brands who have launched successfully elsewhere in the region.
Herbal products, dietary supplements and medicated cosmetics are registered by the Drug Registration department of PDCD — under a dedicated set of registration requirements, not under a food regime.
The practical consequence is documented from an unusually reliable source. The UK Government’s trade barrier register recorded a formal market-access barrier for vitamins and wellbeing products in Qatar, on the specific grounds that Qatar requires a pharmaceutical GMP certificate from vitamin manufacturers who typically do not hold one, and that each product goes through a testing programme comparable to a pharmaceutical.
If your supplement is made on a food-grade line, Qatar may be closed to you until that changes. This is the clearest example we can give of why a pharmaceutical CDMO and a supplement contract manufacturer are not interchangeable.
Qatar operates a two-tier structure. The company is registered before any product can be.
Company tier typically involves a registration certificate from Medical Licensing, an authenticated agency agreement, a GMP certificate and manufacturing licence from the country of origin, evidence of registration in other markets, and a manufacturer relationship letter.
Product tier typically involves a free sale certificate, certificate of composition, certificate of analysis, a CIF price certificate, label and leaflet as used in the country of origin, analytical methods and reference standards, product samples for laboratory testing, and a prohibited-substance certificate.
Documents generally require legalisation and authentication through the Qatar Ministry of Foreign Affairs. This is not a formality — an unauthenticated document does not satisfy the requirement, and this is a routine cause of delay.
Qatar requires positive confirmation that a product is free from hormones, anabolic and anti-inflammatory steroids, psychotropics, alcohol, heavy metals, pathogenic bacteria and fungi, and pork derivatives.
For nutraceutical formulations this reaches deeper into the formula than most brands expect. Gelatin capsules, glycerin, ethanol-based botanical extracts and certain excipients all become dossier questions. These are formulation and sourcing decisions, and they are far cheaper to make at development stage than to unpick after a rejection.
Sports supplements additionally carry a mandatory warning on inner and outer packaging stating that licensing does not guarantee the product is free from banned substances, and that the athlete uses dietary supplements at their own risk of a positive doping test.
A local agent or representative is required in practice — MOPH’s service descriptions are addressed to agents, representatives and importers, and an authenticated agency agreement is a required document.
What deserves genuine caution is the commercial side. Under Qatar’s commercial agents legislation, agency is restricted to Qatari nationals or wholly Qatari-owned companies, a registered agency is treated as automatically exclusive, and termination provisions favour the agent.
Choose your Qatari agent as carefully as you would choose a joint venture partner. This is a matter for qualified legal counsel in Qatar, not a regulatory checkbox, and we will always tell clients so rather than pretend otherwise.
The GCC Centralised Drug Registration procedure, run by the Gulf Health Council, offers a single scientific review recognised across participating Gulf states.
There is a persistent misconception worth correcting: GCC central approval is not a single market authorisation. After central approval, each country still issues its own national registration certificate and its own pricing decision before the product can be sold there.
For Qatar specifically, a GCC approval does not remove the need for a Qatari agent, a Qatari national registration, or Qatari pricing approval. In practice companies use both routes — centralised and direct national — and which makes sense depends on how many Gulf markets you are targeting.
For herbal products, supplements and medicated cosmetics, MOPH’s published requirements indicate labels and leaflets may be in Arabic and/or English, with actives named in both scientific Latin and common English names, and batch and expiry details applied in indelible ink or engraved.
For pharmaceuticals, bilingual Arabic and English is the regional expectation. Our practical advice is to treat Arabic artwork as the commercial default for any Gulf launch, while confirming the legal position for your specific product class — the two are not always the same thing.
We are going to be straight with you, because it affects how you should plan.
Qatar publishes less regulatory detail in accessible English than Saudi Arabia or the UAE, and a good deal of the guidance circulating online is derived from documents that appear to predate 2016. Timelines and fees quoted by consultancies for Qatar vary so widely that we will not repeat any of them.
One point in particular needs checking on every project: some older MOPH documentation lists prior registration in another GCC state among the required documents. If that requirement is current, it would mean Qatar is not a viable first-in-region launch market — which would change your entire sequencing. We verify this directly with PDCD for each engagement rather than assume it either way.
The responsible approach to Qatar is a written enquiry to PDCD, or engagement of a Qatar-licensed regulatory agent, before anything is committed to print or budget. That is how we work.
Tell us the product, the dosage form and where it is manufactured — the manufacturing site is often the deciding factor for Qatar.
Email: info@raisedpharma.com Phone: +1 (716)-777-4800
Request a consultation See all GCC markets
Important: This page is general information about the Qatari regulatory environment, not regulatory or legal advice. Publicly available Qatar guidance is limited and some of it appears to predate 2016; requirements described here must be confirmed directly with the Ministry of Public Health Pharmacy and Drug Control Department before being relied on. Agency arrangements carry legal consequences and require qualified Qatari legal counsel. Nothing here should be relied on for a submission. Last reviewed August 2026.